The U.S. Food and Drug Administration (FDA) has been criticized by Congress for its inaction on regulating CBD products. GOP representative Lisa McClain accused the FDA of asking for more resources before fulfilling its duties. The FDA had previously announced that it needs a new regulatory framework for hemp and CBD. The hearing followed the reintroduction of the Hemp Access and Consumer Safety Act by a bipartisan group of lawmakers, which aims to secure the FDA's regulation of hemp-derived CBD products. The FDA has approved Jazz Pharmaceuticals' Epidiolex, a CBD-based drug for treating severe forms of epilepsy.